Crossbow Therapeutics
PrivateLast Round
Series B
Mar 18, 2026
Est. Valuation
$112.55M
Total Funding Raised
$157M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Crossbow Therapeutics is a biotechnology company developing next-generation T-cell receptor (TCR)-mimetic antibody therapies to treat a broad range of cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Crossbow Therapeutics Comparables
Compare Crossbow Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enara Bio | 81% | |
| BlueSphere Bio | 79% | |
| TScan Therapeutics | 78% |
Crossbow Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 18, 2026 | ||||
| Series A | Jul 11, 2023 |
Key People
Founding team and executive leadership
Crossbow Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Libbs Ventures | Series B |
| LifeLink Ventures | Series B |
| Sixty Degree Capital | Series B |
| Taiho Ventures | Series B |
| MPM BioImpact | Series B, Series A, Seed |
| Arkin Bio Capital | Series B |
| BVF Partners L.P. | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 18, 2026
$77M round completed.
- Mar 18, 2026
Developing novel T-cell engager therapies targeting cancer cells.
Crossbow Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Crossbow Therapeutics's valuation, stock price, and market status.
Is Crossbow Therapeutics a public or private company?
Crossbow Therapeutics is a private company.
What is the current stock price of Crossbow Therapeutics?
Crossbow Therapeutics is a private company, so its shares have no public market price. Caplight tracks Crossbow Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Crossbow Therapeutics worth (valuation)?
Crossbow Therapeutics's valuation is estimated at $112.5M based on funding round data.
Can I buy Crossbow Therapeutics stock?
Crossbow Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Crossbow Therapeutics's last funding round?
Crossbow Therapeutics's most recent funding round was Series B on March 18, 2026.
Who are the main investors in Crossbow Therapeutics?
Key investors in Crossbow Therapeutics include Taiho Ventures, MPM BioImpact, Arkin Bio Capital, Pfizer Ventures, Pfizer.
Will Crossbow Therapeutics IPO soon?
No public IPO plans have been announced for Crossbow Therapeutics.
How can I track Crossbow Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Crossbow Therapeutics's shares on secondary markets.